Bellerophon Therapeutics : Costs Associated with Exit/Disposal

UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


WASHINGTON, D.C. 20549



FORM 8-K



CURRENT REPORT



Pursuant to Section 13 or 15(d) of the Securiti...

Related Keywords

New Jersey ,United States ,Delaware ,Washington ,Parag Shah ,Peter Fernandes ,Martin Dekker ,Company Vice ,Securities Exchange ,Bellerophon Therapeutics Inc ,Securities Exchange Act ,Exact Name ,Principal Executive Offices ,Zip Code ,Former Name ,Former Address ,Changed Since Last Report ,General Instruction ,Securities Act ,Exchange Act ,Bellerophon Therapeutics ,Interstitial Lung Disease ,Certain Officers ,Compensatory Arrangements ,Chief Executive Officer ,Vice President ,Business Operations ,Current Report ,Chief Executive ,Markets ,